Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 20/20 | 1.00 |
| ▸ | HDAC8 | Q9BY41 | 6/20 | 0.75 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.61 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.61 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3369905 | 1.00 | HDAC1 (1.00) | HDAC1HDAC8HDAC3HDAC2HDAC6 | |
| SCHEMBL3369355 | 0.87 | HDAC1 (1.00) | HDAC1HDAC8 | |
| SCHEMBL3369364 | 0.87 | HDAC1 (1.00) | HDAC1HDAC8 | |
| SCHEMBL3368405 | 0.85 | HDAC1 (1.00) | HDAC1HDAC8 | |
| SCHEMBL3368410 | 0.85 | HDAC1 (1.00) | HDAC1HDAC8 | |
| SCHEMBL3369278 | 0.82 | HDAC1 (1.00) | HDAC1HDAC8 | |
| SCHEMBL3369272 | 0.82 | HDAC1 (1.00) | HDAC1HDAC8 | |
| SCHEMBL3369165 | 0.81 | HDAC1 (1.00) | HDAC1HDAC8 | |
| SCHEMBL3369159 | 0.81 | HDAC1 (1.00) | HDAC1HDAC8 | |
| SCHEMBL13227285 | 0.81 | HDAC1 (0.73) | HDAC1HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1476435-B1 | NOVEL PYRIDIN- AND PYRIMIDIN-DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2010-06-30 | — | — | EP | claimed |
| EP-1673349-B1 | BENZIMIDAZOLE DERIVATIVES: PREPARATION AND PHARMACEUTICAL APPLICATIONS | S BIO PTE LTD (SG) | 2010-06-30 | — | — | EP | claimed |
| US-6867205-B2 | Pyridine and pyrimidine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2005-03-15 | — | — | US | claimed |
| EP-1476435-A1 | NOVEL PYRIDIN- AND PYRIMIDIN-DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2004-11-17 | — | — | EP | claimed |
| US-20030216382-A1 | Pyridine and pyrimidine derivatives | HOFFMAN-LA ROCHE INC. | 2003-11-20 | — | — | US | claimed |
| WO-2003068757-A1 | NOVEL PYRIDIN- AND PYRIMIDIN-DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-08-21 | — | — | WO | claimed |
| US-10736881-B2 | Benzimidazole derivatives: preparation and pharmaceutical applications | MEI PHARMA, INC. (US) | 2020-08-11 | — | — | US | disclosed |
| US-20190282547-A1 | BENZIMIDAZOLE DERIVATIVES: PREPARATION AND PHARMACEUTICAL APPLICATIONS | S*BIO PTE LTD. (SG) | 2019-09-19 | — | — | US | disclosed |
| US-10201527-B2 | Benzimidazole derivatives: preparation and pharmaceutical applications | MEI PHARMA, INC. (US) | 2019-02-12 | — | — | US | disclosed |
| US-20170360757-A1 | BENZIMIDAZOLE DERIVATIVES: PREPARATION AND PHARMACEUTICAL APPLICATIONS | S*BIO PTE LTD. (SG) | 2017-12-21 | — | — | US | disclosed |
| US-9717713-B2 | Benzimidazole derivatives: preparation and pharmaceutical applications | MEI PHARMA, INC. (US) | 2017-08-01 | — | — | US | disclosed |
| US-20160279102-A1 | BENZIMIDAZOLE DERIVATIVES: PREPARATION AND PHARMACEUTICAL APPLICATIONS | S*BIO PTE LTD. (SG) | 2016-09-29 | — | — | US | disclosed |
| US-9402829-B2 | Benzimidazole derivatives: preparation and pharmaceutical applications | MEI PHARMA, INC. (US) | 2016-08-02 | — | — | US | disclosed |
| US-7022718-B2 | Pyridine and pyrimidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-04-04 | — | — | US | disclosed |
| US-20050143405-A1 | Pyridine and pyrimidine derivatives | BOEHRINGER MARKUS (CH) | 2005-06-30 | — | — | US | disclosed |
| US-6867205-B2 | Pyridine and pyrimidine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2005-03-15 | — | — | US | disclosed |
| EP-1476435-A1 | NOVEL PYRIDIN- AND PYRIMIDIN-DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2004-11-17 | — | — | EP | disclosed |
| WO-2003068757-A9 | NOVEL PYRIDIN- AND PYRIMIDIN-DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2004-10-07 | — | — | WO | disclosed |
| US-20030216382-A1 | Pyridine and pyrimidine derivatives | HOFFMAN-LA ROCHE INC. | 2003-11-20 | — | — | US | disclosed |
| WO-2003068757-A1 | NOVEL PYRIDIN- AND PYRIMIDIN-DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10201527-B2 | Benzimidazole derivatives: preparation and pharmaceutical applications | HDAC5, HDAC1, HDAC8 | HDAC1 2/4885HDAC8 3/4885HDAC3 7/4885 |
| US-20190282547-A1 | BENZIMIDAZOLE DERIVATIVES: PREPARATION AND PHARMACEUTICAL APPLICATIONS | HDAC5, HDAC1, HDAC8 | HDAC1 2/4885HDAC8 3/4885HDAC3 7/4885 |
| US-20030216382-A1 | Pyridine and pyrimidine derivatives | DPP4, GPR119, G6PC1 | HDAC1 1692/4885HDAC8 3834/4885HDAC3 1296/4885 |
| US-10736881-B2 | Benzimidazole derivatives: preparation and pharmaceutical applications | HDAC5, HDAC1, HDAC8 | HDAC1 2/4885HDAC8 3/4885HDAC3 7/4885 |
| US-20050143405-A1 | Pyridine and pyrimidine derivatives | DPP4, GPR119, PDXK | HDAC1 1981/4885HDAC8 3765/4885HDAC3 1276/4885 |
| US-20160279102-A1 | BENZIMIDAZOLE DERIVATIVES: PREPARATION AND PHARMACEUTICAL APPLICATIONS | HDAC5, HDAC1, HDAC8 | HDAC1 2/4885HDAC8 3/4885HDAC3 7/4885 |
| US-20170360757-A1 | BENZIMIDAZOLE DERIVATIVES: PREPARATION AND PHARMACEUTICAL APPLICATIONS | HDAC5, HDAC1, HDAC8 | HDAC1 2/4885HDAC8 3/4885HDAC3 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.